OpenLobby.EU
Explore

BioPharma First Consultancy

I am committed to delivering expert consultancy, coaching, business and educational services related to the pharmaceutical and health(care) space.

Lobbying Activity

Response to Streamlining EU scientific and technical work on chemicals through the EU agencies

7 Feb 2024

As an Expert for the European Commission (EC) with a focus on the Pharmaceutical, Healthcare and Health sectors, I am eager to contribute to the ongoing social dialogue initiated by the EC. This pertains to the Proposal for Regulation COM(2023)783 and Staff working document SWD(2023)850. Both documents are also related to the document COM(2020)667, 'Communication from the Commission to the European Parliament, the Council, The European Economic and Social Committee and The Committee of the Regions: Chemicals Strategy for Sustainability Towards a Toxic-Free Environment'. The objective is to establish a transparent system, following the principle of One substance, one assessment(OSOA), relying on robust scientific evidence about safety of chemicals. This is aimed at safeguarding EU citizens, ensuring individual health safety, sustainability, environmental safety, and assessing economic, social, and environmental impacts. As indicated by WHO two thirds of deaths are attributed to environmental risk factors and are related to non-communicable diseases (NCDs), such as heart disease, stroke, and cancer. I wish to express my opinions on topics related to COM(2023)783 and SWD(2023)850, including coherence of assessments, the independence of scientific advice, and the promotion of collaboration. Attached, you will find a document addressing selected issues.
Read full response